MedTrace Logo

CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT04626752 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2020-11-13

No results posted yet for this study

Summary

This study is aimed to evaluate the safety, feasibility and efficacy of CAR-T cell therapy in the treatment of relapsed or refractory multiple myeloma

Conditions

Interventions

DRUG

BCMA CAR-T

Volunteers will be treated with BCMA CAR-T cells

DRUG

Fludarabine

25mg/㎡ for D-4、D-3 and D-2

DRUG

Cyclophosphamide

500mg/㎡ for D-3 and D-2

Sponsors & Collaborators

  • Hebei Senlang Biotechnology Inc., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jianmin Luo, PhD&MD · The Second Hospital of Hebei Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-01
Primary Completion
2023-03-30
Completion
2023-03-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04626752 on ClinicalTrials.gov